TrialMed (New York, N.Y.)2025

Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial.

Jeffrey A How et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.